Why Is Ultragenyx Pharmaceutical (RARE) Stock Down -47.42% Today?
Key Takeaways
- RARE shares plunged roughly 47.4% after the company's pivotal Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome failed to meet its primary and key secondary endpoints.
- The trial showed no meaningful difference between the treatment and placebo groups on cognitive and functional measures.
- A wave of analyst downgrades and price-target cuts amplified the selloff, with several firms slashing targets by more than half.
- The stock fell below its prior 52-week low of $18.29 and traded at its lowest level in more than a year.
- Ultragenyx said it will review the apazunersen program and implement "significant expense reductions," shifting its focus to its commercial business.
- Investors are now watching the FDA's Sept. 19 decision on UX111 for Sanfilippo syndrome Type A and details of the company's cost-cutting plan.
Opening Summary
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on rare and ultra-rare genetic diseases, saw its stock collapse on Thursday after its lead late-stage candidate failed a pivotal clinical trial. Shares were trading around $13.95, down from a prior close of $26.53 — a decline of approximately 47.42%. The selloff was driven by the company's announcement that the Phase 3 Aspire study of apazunersen (GTX-102) in Angelman syndrome did not achieve its primary endpoint of cognitive improvement or its key secondary endpoint, triggering a flurry of analyst downgrades and price-target reductions.
Clinical Trial Failure: The Primary Catalyst
The decisive driver behind the move was the failure of the Phase 3 Aspire study. The trial enrolled roughly 129 children aged 4 to 17 with Angelman syndrome, a rare neurodevelopmental disorder characterized by severe developmental delays, limited speech, and seizures. Apazunersen, an antisense oligonucleotide, failed to show a meaningful difference versus placebo on the Bayley-4 cognitive raw score, the study's primary endpoint, or on the Multidomain Responder Index, its key secondary measure.
Because apazunersen had generated strong signals in earlier-stage studies, the complete absence of an efficacy benefit caught many investors off guard. The company noted that the safety profile was consistent with prior Phase 1/2 data, but with no efficacy signal to support the program, management said it would review the future of apazunersen and evaluate its overall operations. This marks Ultragenyx's second consecutive late-stage trial miss, further eroding confidence in the pipeline.
Analyst Downgrades and Price-Target Cuts
The clinical setback triggered an immediate re-rating from Wall Street. Evercore ISI downgraded the stock to In Line from Outperform and cut its price target to $16 from $34, describing the result as a "clean fail." Baird lowered its rating to Neutral from Outperform, reducing its target to $16 from $40, while JPMorgan moved to Neutral from Overweight and cut its target to $36 from $80. William Blair downgraded RARE to Market Perform, removing the GTX-102 contribution from its pipeline valuation. Additional cuts came from Wells Fargo, H.C. Wainwright, Citi, and Canaccord, collectively reflecting a sharp reset in expectations for the company's growth trajectory.
Strategic and Financial Implications
Beyond the trial itself, the failure removes what many analysts had viewed as a key growth driver and the company's path toward profitability. Ultragenyx said it will implement "significant expense reductions" while supporting its commercial portfolio, which includes therapies such as Crysvita, Dojolvi, Mepsevii, and the recently approved gene therapy Genglycos. The company remains cash-flow negative, and analysts highlighted ongoing cash consumption and the eventual loss of Crysvita exclusivity as additional concerns. The setback also raises questions about the ongoing Aurora study, a broader basket trial of apazunersen.
Market Context and Trading Activity
The move in RARE was stock-specific rather than sector-driven. Broader U.S. equity indices were modestly higher during the session, underscoring that the decline was tied to company news rather than macro or biotech-sector weakness. Trading volume was heavy, running well above typical levels as investors repositioned following the announcement. The stock broke decisively below its previous 52-week low of $18.29, establishing a new multi-year low and signaling a clear technical breakdown that left little near-term support in place.
What Comes Next for RARE
Attention now turns to several near-term events. The FDA is expected to decide by Sept. 19, 2026 on Ultragenyx's resubmitted application for accelerated approval of UX111, a gene therapy for Sanfilippo syndrome Type A. A positive decision could provide a modest catalyst, though analysts caution it is likely to be incremental. Investors will also be watching for details of the company's expense-reduction plan and any decision on the future of the apazunersen program. Key risks include further pipeline setbacks, execution challenges in the commercial business, and sustained cash burn. The investment case has shifted from pipeline-driven growth toward commercial execution and cost discipline, and how management navigates that transition will shape sentiment in the months ahead.
Trending AI Robots
For traders seeking a more systematic approach to volatile moves like this, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches tailored to different market environments. Explore the Trending AI Robots to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
RARE in +3.96% Uptrend, growing for three consecutive days on October 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RARE advanced for three days, in 219 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RARE's RSI Oscillator exited the oversold zone, 26 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for RARE just turned positive on September 22, 2026. Looking at past instances where RARE's MACD turned positive, the stock continued to rise in 37 of 49 cases over the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 59 cases where RARE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RARE as a result. In 64 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The 50-day moving average for RARE moved below the 200-day moving average on September 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for RARE entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. RARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RARE's P/B Ratio (250.000) is slightly higher than the industry average of (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1.809) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics for rare diseases
Industry Biotechnology
Advertisement